G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $6.82
    -0.14 (-2.08%)

    Market Cap: $468.69M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(8/20)
    Avg Surprise
    -306.16%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.58
    Range$-0.58 - $-0.58
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.58
    Revenue Consensus
    $21M
    Range$21M - $21M
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.58
    Range$-0.58 - $-0.58
    1 analysts
    Revenue Consensus
    $-6110000
    Range$-6460000 - $-5760000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.58---
    Sep 26EST
    		-$-0.58---
    Jun 26
    		$-0.86$-0.70-22.86%Miss+21.8%
    Mar 26
    		$-1.39$-1.34-3.73%Miss+17.3%
    Dec 25
    		$-1.42$-1.80+21.11%Beat+29.0%
    Sep 25
    		$-1.45$-1.24-16.94%Miss-34.3%
    Jun 25
    		$-1.10$-1.44+23.61%Beat+75.0%
    Mar 25
    		$-1.68$-1.77+5.08%Beat-2000.0%
    Dec 24
    		$-2.00$-0.06-3330.53%Miss+32.0%
    Sep 24
    		$-1.08N/A+67.47%Beat+70.4%
    Jun 24
    		$-4.40$-3.12-41.03%Miss-43.8%
    Mar 24
    		$-0.08$-0.08+0.00%Beat+97.9%
    Dec 23
    		$-2.94$-2.80-5.00%Miss-3166.7%
    Sep 23
    		$-3.65$-3.20-14.06%Miss+77.9%
    Jun 23
    		$-3.06$-3.50+12.57%Beat+81.4%
    Mar 23
    		$-3.89$-3.90+0.26%Beat+73.7%
    Dec 22
    		$-0.09N/A+57.14%Beat+90.9%
    Sep 22
    		$-16.51$-9.68-70.56%Miss-415.9%
    Jun 22
    		$-16.44$-5.44-202.21%Miss-3188.0%
    Mar 22
    		$-14.80$-7.40-100.00%Miss-49433.3%
    Dec 21
    		$-0.99$-0.04-2375.00%Miss-
    Sep 21
    		$-3.20$-1.40-128.57%Miss-
    Jun 21
    		$-0.50N/AN/ABeat-
    Mar 21
    		$0.03$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.33EV/EBITDA-1.79x
    Price/FCF-2.32xFCF Yield-43.12%
    Profitability
    Profit Margin-219.60%Operating Margin-285.00%
    ROE-59.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-54.64x
    Current Ratio4.57xQuick Ratio4.57x
    Trading Statistics
    Beta1.79Avg Volume1.28M
    52-Week High$17.5852-Week Low$5.37

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.12
    SMA 20$7.49
    SMA 50$8.30
    SMA 200$8.33
    EMA 10$7.15
    EMA 20$7.39
    EMA 50$7.88
    EMA 200$8.56

    MACD

    Line: -0.34Signal: -0.34Hist: 0.01

    ADX

    ADX: 17.5+DI: 17.3-DI: 25.6

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down64.0
    PSAR$6.56

    Bollinger Bands

    Upper Band$9.07
    Lower Band$5.90
    %B Position4233%(Upper)
    Band Width0.29

    RSI (14-Day)

    Neutral
    42.6

    Momentum Oscillators

    Stoch %K36.2
    Stoch %D39.2
    Williams %R-73.0
    ROC (10d)-1.5%
    Momentum-0.10
    CCI (20d)-83.6
    MFI (14d)39.7

    Volatility Measures

    ATR (14d)$0.56(8.2%)
    StdDev (20d)0.79
    Hist Vol110.9%(High)

    Volume Flow

    VWAP$6.82
    OBV10.5M
    AD Line-17.0M
    CMF (20d)-0.176

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.9x
    VWMA (20d)$7.52

    Pivot Points

    R3$7.57
    R2$7.43
    R1$7.19
    Pivot Point$7.05
    S1$6.82
    S2$6.68
    S3$6.44

    Advanced Oscillators

    TSI-12.34
    Ultimate Osc48.3
    KST-154.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.16M$19.47M$33.40M$38.84M$39.13M$38.23M$43.85M$89.05M$56.21M$37.94M$34.76M$55.43M
    Cost of Revenue$1.72M$3.10M$-8,505,000$12.80M$5.38M$4.09M$-11,387,000$12.00M$25.53M$18.40M$6.61M$6.92M
    Gross Profit$18.44M$16.38M$41.90M$26.04M$33.75M$34.14M$55.23M$77.04M$30.68M$19.54M$28.14M$48.51M
    Operating Expenses$76.98M$87.75M$96.85M$116.05M$91.92M$115.11M$137.83M$132.25M$265.43M$206.74M$206.26M$334.90M
    R&D$46.21M$49.92M$50.13M$69.35M$53.37M$70.92M$76.38M$77.01M$134.22M$136.46M$117.04M$156.66M
    SG&A$30.77M$37.83M$46.01M$44.95M$34.98M$39.72M$57.30M$52.29M$66.28M$70.29M$89.22M$82.03M
    Operating Income$-58,548,000$-71,374,000$-65,937,000$-90,017,000$-58,163,000$-80,972,000$-100,163,000$-55,204,000$-226,388,000$-178,002,000$-178,117,000$-286,393,000
    Interest Income$-2,686,000$-1,214,000$6.44M$3.68M$-229,000$-3,693,000$19.05M$-6,912,000$-6,826,000$-2,544,000$3.58M$-36,324,000
    Interest Expense$-3,232,000$-3,596,000$17.91M$-5,742,000$-6,083,000$-6,081,000$31.37M$-9,251,000$-10,313,000$-11,711,000$44.01M$-15,020,000
    Income Before Tax$-57,193,000$-76,139,000$-81,394,000$-80,754,000$-53,477,000$-83,222,000$-107,859,000$-56,778,000$-216,991,000$-165,880,000$-211,892,000$-302,913,000
    Income Tax Expense$128,000$-80,000$-643,000$1,000$-283,000$88,000$-325,000$-375,000$190,000$31,000$-198,000$-22,000
    Net Income$-46,710,000$-82,587,000$-80,751,000$-80,755,000$-60,300,000$-90,957,000$-107,534,000$-56,403,000$-217,181,000$-165,911,000$-211,694,000$-302,891,000
    EBITDA$-45,424,000$-65,722,000$-51,453,000$-76,012,000$-44,082,000$-70,788,000$-76,449,000$-41,948,000$-206,591,000$-162,178,000$-158,632,000$-260,549,000
    EBIT$-57,739,000$-78,521,000$-65,116,000$-90,180,000$-59,331,000$-85,610,000$-92,101,000$-59,117,000$-223,921,000$-175,047,000$-171,469,000$-281,609,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNA

    Government Contracts

    Gov Obligations (TTM)
    $26.59M
    Gov Obligations / Revenue
    17.6%
    Obligations YoY
    -60.5%
    Active Awards
    4
    New Awards (TTM)
    1
    Avg Remaining Term
    17.9 mo

    Top agency: Department of Health and Human Services at 95.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75D30126F00004Department of Health and Human ServicesCenters for Disease Control and Prevention$3.20MMay 3, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock By Investing.com

    Ginkgo Bioworks CFO Steven Coen sold 330 shares of Class A Common Stock for $2,302 to cover tax withholding obligations. This transaction followed his acquisition of 743 shares through RSU vesting. The company recently reported a smaller-than-expected loss but a significant revenue shortfall in Q2 2026, leading to a downgrade from TD Cowen.

    Investing.com South Africa•8/25/26•
    Somewhat-Bearish

    Ginkgo Bioworks (DNA) CFO logs 743 RSU vesting, tax sale

    Ginkgo Bioworks CFO Steven P. Coen reported the vesting of 743 Restricted Stock Units (RSUs) on August 21, 2026, which converted into Class A Common shares. Subsequently, on August 24, 2026, Coen sold 330 shares of Class A Common Stock at $6.977 per share to fulfill tax withholding obligations related to the vesting. The company clarified that these "sell-to-cover" transactions were not discretionary trades by the CFO.

    Stock Titan•8/25/26•
    Neutral

    Ginkgo Bioworks (DNA) officer to sell 330 shares for taxes after vesting

    Ginkgo Bioworks officer Steven P. Coen has filed a notice to sell 330 Class A common shares worth $2,302.47 to cover tax obligations from a vested equity award. This follows a previous sale of 752 shares on July 17, 2026, for $5,943.28. The transaction, filed under Rule 144, relates to restricted stock vesting classified as compensation.

    Stock Titan•8/24/26•
    Neutral

    Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale

    An insider at Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), Austin Che, has filed a Form 144 indicating a proposed sale of 2,200 Class A shares with an aggregate market value of $14,652.00. These shares stem from restricted stock vesting awards in October 2022. The filing also notes a previous sale of 2,200 Class A shares for $17,732.00 on June 10, 2026, within the last three months.

    Stock Titan•8/17/26•
    Neutral

    How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing

    The article analyzes Ginkgo Bioworks Holdings Inc. Class A (DNA) stock performance and its impact on rotational strategy timing. It highlights a weak sentiment signaling long-term weakness resumption and identifies a significant short setup with a 100.0:1 risk-reward ratio. The report provides three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and a multi-timeframe signal analysis for DNA.

    Stock Traders Daily•8/16/26•
    Bearish

    Frequently Asked Questions About DNA

    Does DNA pay dividends?
    Ginkgo Bioworks Holdings (DNA) does not currently pay a regular dividend.
    What is DNA's market cap?
    Ginkgo Bioworks Holdings (DNA) has a market capitalization of $468.69M with a current stock price of $6.82.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In